Shukra Pharma.

Why is Shukra Pharmaceuticals Ltd falling/rising?

As of 12-Jun, Shukra Pharmaceuticals Ltd's stock price has risen by 2.78% to 29.97, outperforming its sector. Despite recent declines over the past month and week, the stock has shown significant long-term growth, with a 101.01% increase over the last year, though it trades at a premium compared to peers.

As of 12-Jun, Shukra Pharmaceuticals Ltd's stock price is rising, as indicated by a change of 0.81, or 2.78%, in the current price of 29.97. This increase is notable given the stock's performance today, where it outperformed its sector by 2.25%. <BR><BR>Despite a recent decline in stock performance over the past week and month, where it fell by 4.74% and 1.02% respectively, the stock has shown significant long-term growth, with a remarkable increase of 101.01% over the last year and an impressive 580.94% over the past three years. The company's net sales and profit after tax for the latest six months have also shown positive growth, with net sales at Rs 45.43 crore and PAT at Rs 18.63 crore.<BR><BR>However, it is important to note that the stock is trading at a premium compared to its peers, with a high Price to Book Value ratio of 20, which may indicate a very expensive valuation. Additionally, the falling investor participation, as evidenced by an 8.82% decline in delivery volume against the 5-day average, could suggest some caution among investors. Despite this, the overall positive financial indicators and recent price increase reflect a current upward movement in the stock price.

Which are the latest news on Shukra Pharma.?

How big is Shukra Pharma.?

As of 10th June, Shukra Pharmaceuticals Ltd has a market capitalization of 1,368.00 Cr, with recent net sales of 64.60 Cr and a net profit of 26.41 Cr. The balance sheet for March 2025 shows shareholder's funds of 62.84 Cr and total assets of 86.77 Cr.

As of 10th June, Shukra Pharmaceuticals Ltd has a market capitalization of 1,368.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Shukra Pharmaceuticals reported Net Sales of 64.60 Cr and a Net Profit of 26.41 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, showing Shareholder's Funds of 62.84 Cr and Total Assets of 86.77 Cr.

Who are in the management team of Shukra Pharma.?

The management team of Shukra Pharma includes Dakshesh Shah (Chairman & Managing Director), Payal Mehta, Sanskruti Patel, and Dhruvin Shah (all Executive Directors), along with independent directors Bhoomiben Patel, Sarjeevan Singh, Sonal Deepalbhai Gandhi, and Pinki Nirmal Sagar. This diverse team combines executive and independent expertise in its leadership.

The management team of Shukra Pharma includes the following individuals:<BR><BR>1. **Dakshesh Shah** - Chairman & Managing Director<BR>2. **Payal Mehta** - Executive Director<BR>3. **Sanskruti Patel** - Executive Director<BR>4. **Dhruvin Shah** - Executive Director<BR>5. **Bhoomiben Patel** - Independent Director<BR>6. **Sarjeevan Singh** - Independent Director<BR>7. **Sonal Deepalbhai Gandhi** - Independent Director<BR>8. **Pinki Nirmal Sagar** - Independent Director<BR><BR>This team brings a mix of executive and independent perspectives to the company's leadership.

Who are the peers of the Shukra Pharma.?

Shukra Pharma's peers include Hester Bios, Amrutanjan Health, Ind-Swift Labs, Jagsonpal Pharma, Syncom Formulations, Lincoln Pharma, Fredun Pharma, Fermenta Biotec, Beta Drugs Ltd, and Accent Microcell. Shukra Pharma shows excellent growth and a 1-year return of 116.01%, outperforming peers like Amrutanjan Health, which has the lowest return at -19.65%.

Peers: Hester Bios, Amrutanjan Healt, Ind-Swift Labs., Shukra Pharma., Jagsonpal Pharma, Syncom Formul., Lincoln Pharma., Fredun Pharma, Fermenta Biotec., Beta Drugs Ltd, Accent Microcell.<BR><BR>Quality Snapshot: Excellent management risk is observed at Amrutanjan Healt, while Average management risk is found at Hester Bios, Jagsonpal Pharma, Syncom Formul., Lincoln Pharma, Fredun Pharma, Fermenta Biotec., Beta Drugs Ltd, and Accent Microcell. Growth is Excellent at Shukra Pharma and Fredun Pharma, while Below Average growth is noted at Hester Bios, Amrutanjan Healt, Ind-Swift Labs., Jagsonpal Pharma, Syncom Formul., Lincoln Pharma, and Fermenta Biotec. Capital Structure is Excellent at Amrutanjan Healt, Jagsonpal Pharma, Syncom Formul., Lincoln Pharma, and Beta Drugs Ltd, while Below Average is seen at Hester Bios, Ind-Swift Labs., Fermenta Biotec., and the rest.<BR><BR>Return Snapshot: Fredun Pharma has the highest 1-year return at 211.49%, while Amrutanjan Healt has the lowest at -19.65%. Shukra Pharma's 1-year return of 116.01% is significantly higher than Amrutanjan Healt's. Additionally, Ind-Swift Labs., Syncom Formul., and Fermenta Biotec. have negative six-month returns.

What does Shukra Pharma. do?

Shukra Pharmaceuticals Ltd manufactures and trades pharmaceutical formulations and conducts laboratory testing. Established in 1993, it has a market cap of INR 1,368 Cr, with recent net sales of 6 Cr and a net profit of -2 Cr for the quarter ending March 2026.

Overview: <BR>Shukra Pharmaceuticals Ltd is engaged in the manufacturing and trading of pharmaceutical formulations and laboratory testing within the Pharmaceuticals & Biotechnology industry, classified as a Micro Cap company.<BR><BR>History: <BR>Shukra Pharmaceuticals Ltd was established in March 1993, originally under the name Relish Pharmaceuticals Limited, which was changed to its current name effective September 22, 2016. The latest quarterly results reported net sales and profit for the period ending March 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 6 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: -2 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 1,368 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 52.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.03% <BR>Debt-Equity: -0.15 <BR>Return on Equity: 33.49% <BR>Price to Book: 20.61 <BR><BR>Contact Details: <BR>Address: 3 rd Floor Dev House, Opp WIAA Office Judges Bungalo Ahmedabad Gujarat : 380054 <BR>Tel: 91-079-66522247/27498515 <BR>Email: info@relishpharma.com <BR>Website: http://www.shukrapharmeceuticals.com

Are Shukra Pharmaceuticals Ltd latest results good or bad?

Shukra Pharmaceuticals Ltd's latest results are concerning, showing an 83.85% decline in revenue and a net loss of ₹1.72 crores in Q4 FY26, indicating significant operational challenges. While the six-month performance shows some profit, the drastic quarterly drop raises caution for investors.

Shukra Pharmaceuticals Ltd's latest results indicate a challenging quarter. In Q4 FY26, the company reported a significant decline in revenue, which fell by 83.85% quarter-on-quarter to ₹6.32 crores from ₹39.13 crores in the previous quarter. This drastic drop in revenue is concerning and raises questions about the company's operational consistency.<BR><BR>Additionally, the net profit for the quarter was a loss of ₹1.72 crores, marking a decline of 108.45% compared to the previous quarter's profit. The operating margin also compressed sharply to 11.08%, down from an exceptional 69.33% in Q3 FY26. <BR><BR>While the six-month view shows a cumulative net profit of ₹18.63 crores, suggesting that the quarterly weakness may be an anomaly rather than a trend, the extraordinary tax charge of ₹2.10 crores, which resulted in an effective tax rate of 552.63%, further complicates the picture. <BR><BR>Overall, the latest results are not favorable, reflecting significant volatility and operational challenges for Shukra Pharmaceuticals. Investors should be cautious and consider the implications of this performance on the company's future prospects.

Should I buy, sell or hold Shukra Pharmaceuticals Ltd?

When is the next results date for Shukra Pharmaceuticals Ltd?

The next results date for Shukra Pharmaceuticals Ltd is 07 May 2026.

The next results date for Shukra Pharmaceuticals Ltd is scheduled for 07 May 2026.

Is Shukra Pharma. technically bullish or bearish?

As of December 4, 2025, the technical trend has shifted to bullish, supported by strong indicators like bullish MACD and Bollinger Bands, despite a mildly bearish KST signal on the monthly chart.

As of 4 December 2025, the technical trend has changed from mildly bullish to bullish. The current stance is bullish with strong indicators supporting this view. The weekly and monthly MACD are both bullish, and Bollinger Bands also indicate a bullish trend on both time frames. Daily moving averages confirm a bullish outlook. Although the KST shows a mildly bearish signal on the monthly, the overall strength of the bullish indicators outweighs this. The stock has demonstrated significant outperformance compared to the Sensex over multiple time frames, further reinforcing the bullish sentiment.

How has been the historical performance of Shukra Pharma.?

Shukra Pharma's historical performance shows significant fluctuations, with net sales rising from INR 5.69 crore in March 2019 to INR 32.59 crore in March 2025, despite a decline from INR 74.57 crore in March 2024. While total assets and cash flow improved, recent decreases in sales and profits suggest potential challenges ahead.

Answer:<BR>The historical performance of Shukra Pharma shows significant fluctuations in its financial metrics over the years, particularly from March 2019 to March 2025.<BR><BR>Breakdown:<BR>Shukra Pharma's net sales have seen a dramatic increase from INR 5.69 crore in March 2019 to INR 32.59 crore in March 2025, although there was a notable decline in sales from INR 74.57 crore in March 2024. Total operating income followed a similar trend, peaking at INR 74.57 crore in March 2024 before dropping to INR 32.59 crore in March 2025. The company's total expenditure, excluding depreciation, also fluctuated, reaching INR 55.17 crore in March 2024 and decreasing to INR 19.86 crore in March 2025. Operating profit (PBDIT) showed a peak of INR 22.22 crore in March 2024, followed by a decline to INR 16.94 crore in March 2025. Profit before tax reached its highest at INR 19.88 crore in March 2024, then fell to INR 13.34 crore in March 2025, while profit after tax also decreased from INR 18.54 crore in March 2024 to INR 9.58 crore in March 2025. The company's total assets increased from INR 33.55 crore in March 2020 to INR 86.77 crore in March 2025, reflecting growth in both current and non-current assets. Total liabilities also rose, from INR 33.55 crore in March 2020 to INR 86.77 crore in March 2025, indicating an increase in financial obligations. Cash flow from operating activities improved significantly, showing a positive cash flow of INR 7 crore in March 2025 compared to a negative cash flow of INR 5 crore in March 2024. Overall, while Shukra Pharma has experienced growth in certain areas, the recent decline in sales and profits indicates potential challenges ahead.

Is Shukra Pharma. overvalued or undervalued?

As of May 7, 2024, Shukra Pharma is considered very expensive and overvalued with a PE Ratio of 63.03, significantly higher than its peers, despite a 54.08% return over the past year, indicating a lack of growth expectations.

As of 7 May 2024, the valuation grade for Shukra Pharma. has moved from expensive to very expensive, indicating a significant shift in its perceived value. The company is currently considered overvalued. Key ratios include a PE Ratio of 63.03, an EV to EBITDA of 46.20, and a Price to Book Value of 11.12, all of which are substantially higher than industry averages.<BR><BR>In comparison to its peers, Shukra Pharma.'s PE Ratio is notably higher than Sun Pharma. (35.25) and Cipla (22.99), which are categorized as expensive and attractive, respectively. Additionally, while Divi's Lab is also classified as very expensive with a PE of 79.33, Shukra Pharma. still stands out with a significantly lower PEG Ratio of 0.00, suggesting a lack of growth expectations. Notably, Shukra Pharma. has outperformed the Sensex over the past year with a return of 54.08% compared to the Sensex's 7.65%, further complicating its valuation narrative.

Who are the top shareholders of the Shukra Pharma.?

The top shareholders of Shukra Pharma are Anar Project Private Limited with 18.78% and Yogesh Biharilal Parikh with 19.18%. Individual investors hold 9.29%, with no pledged promoter holdings or mutual funds/foreign institutional investors involved.

The top shareholders of Shukra Pharma include Anar Project Private Limited, which holds the highest promoter stake at 18.78%. Additionally, the highest public shareholder is Yogesh Biharilal Parikh, who owns 19.18%. Individual investors collectively hold 9.29% of the company’s shares. Notably, there are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors holding shares.

What is the bonus history of the Shukra Pharma.?

Shukra Pharma recently announced a 3:1 bonus issue, with an ex-date of April 19, 2024, and a record date of April 20, 2024. Shareholders will receive three additional shares for every one share held.

Shukra Pharma has a recent bonus issue history where they announced a 3:1 bonus. The ex-date for this bonus issue is set for April 19, 2024, and the record date is April 20, 2024. This means that for every one share held, shareholders will receive three additional shares. If you have any more questions about the company or its activities, feel free to ask!

Has Shukra Pharma. declared dividend?

Yes, Shukra Pharmaceuticals Ltd has declared a 10% dividend, amounting to 1 per share, with an ex-date of September 23, 2024. Despite recent periods showing no dividend returns, the company has demonstrated exceptional price performance over the years.

Shukra Pharmaceuticals Ltd has declared a 10% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 10%<BR>- Amount per share: 1 per share<BR>- Ex-date: 23 Sep 24<BR><BR>Dividend Yield: 0.74%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was 123.5%, with no dividend return, resulting in a total return of 123.5%.<BR><BR>Over the past year, the price return was 48.12%, with no dividend return, leading to a total return of 48.12%.<BR><BR>In the last 2 years, the price return was 280.55%, with no dividend return, resulting in a total return of 280.55%.<BR><BR>Over the last 3 years, the price return was 3587.56%, with a dividend return of 9.64%, culminating in a total return of 3597.2%.<BR><BR>In the past 4 years, the price return was 3975.57%, with a dividend return of 16.88%, leading to a total return of 3992.45%.<BR><BR>Over the last 5 years, the price return was 8670.9%, with a dividend return of 31.45%, resulting in a total return of 8702.35%.<BR><BR>Overall, Shukra Pharmaceuticals Ltd has declared a dividend, and despite the recent periods showing no dividend returns, the total returns over the years have been exceptionally high, indicating strong price performance.